Cynata Therapeutics has announced the 100-day primary evaluation period has been completed for the last participant enrolled in its phase II clinical trial of CYP-001 in adults with acute graft versus ...

Sex differences in the prevalence, severity, and disability associated with pain are well documented in both clinical and preclinical research. Despite ...

ENLIGHT project brought together Rousselot, Readily3D and other partners to advance 3D bioprinting for diabetes research.

Aspen's sasineprocel is an autologous induced pluripotent stem cell (iPSC) derived dopaminergic neuron precursor cell (DANPC) ...

Explore the implications of the IVNS1ABP gene in a new genetic disease linked to premature aging and neurological decline.

Cynata says Japan’s conditional approval of two induced pluripotent stem cell therapies marks first regulatory validation of ...

The Berlin/Boston-based startup is building vascularised tissue today, with a long-term ambition to manufacture fully ...

XCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today ...

The Rocky Mountain Collegian Sponsored Content Comprehending "Where do stem cells come from?" is essential in understanding ...

Researchers have defined a new genetic disease caused by a mutation in the IVNS1ABP gene. The condition marks a rare ...

Four types of lung cells — including immune cells — function together on a chip environment that simulates respiration and ...